Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
2007 1
2012 1
2013 3
2014 5
2015 3
2016 1
2017 1
2018 4
2019 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Electromagnetic-guided placement of nasoduodenal feeding tubes versus endoscopic placement: a randomized, multicenter trial.
Kappelle WFW, Walter D, Stadhouders PH, Jebbink HJA, Vleggaar FP, van der Schaar PJ, Kappelle JW, van der Tweel I, Van den Broek MFM, Wessels FJ, Siersema PD, Monkelbaan JF. Kappelle WFW, et al. Among authors: stadhouders ph. Gastrointest Endosc. 2018 Jan;87(1):110-118. doi: 10.1016/j.gie.2017.05.033. Epub 2017 Jun 1. Gastrointest Endosc. 2018. PMID: 28579349 Clinical Trial.
Risk factors for primary sclerosing cholangitis.
Boonstra K, de Vries EM, van Geloven N, van Erpecum KJ, Spanier M, Poen AC, van Nieuwkerk CM, Witteman BJ, Tuynman HA, Naber AH, Kingma PJ, Beuers U, Ponsioen CY; Epi PSC PBC Study Group. Boonstra K, et al. Liver Int. 2016 Jan;36(1):84-91. doi: 10.1111/liv.12894. Epub 2015 Aug 28. Liver Int. 2016. PMID: 26077553
Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, Kuiper H, Nix GA, Becx MC, Hoek AC, van Houte DP, Rijk MC, Salemans JM, Scherpenisse J, Schrijver M, Smit AM, Spoelstra P, Stadhouders PH, Tan TG, Hop WC, ten Kate FJ, vanBerge-Henegouwen GP, Schalm SW, van Buuren HR. van Hoogstraten HJ, et al. Among authors: stadhouders ph. J Hepatol. 1998 Sep;29(3):417-23. doi: 10.1016/s0168-8278(98)80059-7. J Hepatol. 1998. PMID: 9764988 Clinical Trial.
HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1.
van Gerven NM, de Boer YS, Zwiers A, Verwer BJ, Drenth JP, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Vrolijk JM, Coenraad MJ, Kraal G, Mulder CJ, van Nieuwkerk CM, Bloemena E, Verspaget HW, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G; Dutch Autoimmune Hepatitis Study Group. van Gerven NM, et al. Genes Immun. 2015 Jun;16(4):247-52. doi: 10.1038/gene.2014.82. Epub 2015 Jan 22. Genes Immun. 2015. PMID: 25611558
18 results